Latest Lapatinib Stories
By Liz Szabo Barbara Bradfield has lived to see dramatic changes in breast cancer. When she was diagnosed in 1989, Bradfield's tumor -- which produced an overabundance of a protein called HER2 -- was considered especially deadly.
By Martin Eatock A new drug called Lapatinib was recently hailed a "big step forward" for women suffering from advanced breast cancer.
Wayne State University researchers say a breast cancer vaccine completely eliminated HER2-positive tumors in mice -- without any toxicity.
Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data from its ongoing Phase I/II clinical trial of ispinesib were presented in a poster at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium held on September 5-7, 2008 in Washington, DC.
Many breast cancers are made worse by the hormone oestrogen and women take drugs known as aromatase inhibitors to reduce the oestrogen in their body and restrict the cancer's progress.
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data from an ongoing Phase I/II clinical trial of ispinesib are scheduled to be presented as a poster presentation at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, to be held September 5-7, 2008 at the Hilton Washington in Washington, DC.
Peregrine Pharmaceuticals has announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer.
The UK's cost-effectiveness watchdog NICE has delivered another blow to the developers of targeted cancer therapies by recommending against the use of four new kidney cancer drugs in the UK.
GlaxoSmithKline plans to renegotiate with the UK's Department of Health as part of its attempt to reverse the National Health Service's decision regarding the company's cancer drug Tyverb, reported the Financial Times.
Ariad Pharmaceuticals has initiated a Phase II clinical trial to examine the efficacy and safety of oral deforolimus, its investigational mTOR inhibitor, in patients with advanced breast cancer.
- totally perplexed and mixed up.